Key clinical point: Dupilumab was more effective than topical corticosteroids (TCS) and cyclosporine in reducing the severity of atopic dermatitis (AD) and transepidermal water loss (TEWL), both in eczematous lesions and nonlesioned skin.
Major finding: At week 16, a higher proportion of patients receiving dupilumab vs cyclosporine or TCS achieved 50% improvement in the Eczema Area and Severity Index (EASI-50; 81.8% vs 28.6% or 40.0% respectively; P = .004 ). TEWL reduced with both dupilumab ( P < .001) and TCS ( P = .047) in eczematous lesions and with dupilumab in nonlesioned skin ( P = .006) with dupilumab treatment being associated with achievement of EASI-50 (odds ratio 10.67; P = .026) and 50% improvement in TEWL ( P = .004).
Study details: Findings are from a prospective, observational study including 46 patients with AD who received TCS (n = 10), cyclosporine (n = 14), or dupilumab (n = 22).
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Montero-Vilchez T et al. Dupilumab improves skin barrier function in adults with atopic dermatitis: A prospective observational study. J Clin Med. 2022;11(12):3341 (Jun 10). Doi: 10.3390/jcm11123341